Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer

Bibliography

• Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33-64, 1
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008;(218):12-20
   PubMedGoogle Scholar
• Teppo L, Dickman PW, Hakulinen T, Cancer patient survival – patterns, comparisons, trends – a population-based Cancer Registry study in Finland. Acta Oncol 1999;38(3):283-94
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind Ch. TNM Classification of malignant tumors. J. Wiley, New York: 1997
   Google Scholar
• Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46(2):170-6
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5(9):713-25
   PubMed Web of Science ®Google Scholar
• Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54(3):784-8
   PubMed Web of Science ®Google Scholar
• Heney NM, Ahmed S, Flanagan MJ, Superficial bladder cancer: progression and recurrence. J Urol 1983;130(6):1083-6
   PubMed Web of Science ®Google Scholar
• Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15(2):84-8
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF, Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13(6):1404-8
   PubMed Web of Science ®Google Scholar
• Pagano F, Garbeglio A, Milani C, Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 1987;13(3):145-9
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999;86(10):2102-8
   PubMed Web of Science ®Google Scholar
• Cookson MS, Herr HW, Zhang ZF, The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158(1):62-7
   PubMed Web of Science ®Google Scholar
• Leblanc B, Duclos AJ, Benard F, Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 1999;162(6):1946-50
   PubMed Web of Science ®Google Scholar
• Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 2008;53(6):1138-48
   PubMed Web of Science ®Google Scholar
• Tritschler S, Scharf S, Karl A, Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007;51(2):403-7; discussion 407-8
   PubMed Web of Science ®Google Scholar
• See WA, Fuller JR. Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am 1992;19(4):663-83
   PubMed Web of Science ®Google Scholar
• Rintala E, Jauhiainen K, Rajala P, Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 1995;154(6):2050-3
   PubMed Web of Science ®Google Scholar
• Barentsz JO, Jager GJ, Witjes JA, Ruijs JH. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur Radiol 1996;6(2):129-33
   PubMed Web of Science ®Google Scholar
• Badalament RA, Gay H, Cibas ES, Monitoring endoscopic treatment of superficial bladder carcinoma by postoperative urinary cytology. J Urol 1987;138(4):760-2
   PubMed Web of Science ®Google Scholar
• Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999;87(3):118-28
   PubMed Web of Science ®Google Scholar
• Murphy WM, Soloway MS, Jukkola AF, Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer 1984;53(7):1555-65
   PubMed Web of Science ®Google Scholar
• Badalament RA, Herr HW, Wong GY, A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987;5(3):441-9
   PubMed Web of Science ®Google Scholar
• Esposti PL, Edsmyr F, Tribukait B. The role of exfoliative cytology in the management of bladder carcinoma. Urol Res 1978;6(4):197-200
   PubMed Web of Science ®Google Scholar
• Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995;153(3 Pt 1):564-72
   PubMed Web of Science ®Google Scholar
• Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985;29(5):810-6
   PubMed Web of Science ®Google Scholar
• Rubben H, Bubenzer J, Bokenkamp K, Grading of transitional cell tumours of the urinary tract by urinary cytology. Urol Res 1979;7(2):83-91
   PubMed Web of Science ®Google Scholar
• Hatch TR, Barry JM. The value of excretory urography in staging bladder cancer. J Urol 1986;135(1):49
   PubMed Web of Science ®Google Scholar
• Sorahan T, Lancashire RJ, Sole G. Urothelial cancer and cigarette smoking: findings from a regional case-controlled study. Br J Urol 1994;74(6):753-6
   PubMedGoogle Scholar
• Castelao JE, Yuan JM, Skipper PL, Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001;93(7):538-45
   PubMed Web of Science ®Google Scholar
• Wallerand H, Bakkar AA, de Medina SG, Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005;26(1):177-84
   PubMed Web of Science ®Google Scholar
• Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997;8(3):444-72
   PubMed Web of Science ®Google Scholar
• Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990;17(3):371-91
   PubMed Web of Science ®Google Scholar
• Durkee C, Benson R Jr. Bladder cancer following administration of cyclophosphamide. Urology 1980;16(2):145-8
   PubMed Web of Science ®Google Scholar
• Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol 2007;18(3):431-46
   PubMed Web of Science ®Google Scholar
• Chiu HF, Tsai SS, Yang CY. Nitrate in drinking water and risk of death from bladder cancer: an ecological case-control study in Taiwan. J Toxicol Environ Health A 2007;70(12):1000-4
   PubMed Web of Science ®Google Scholar
• Zeegers MP, Selen RF, Kleinjans JC, Nitrate intake does not influence bladder cancer risk: the Netherlands cohort study. Environ Health Perspect 2006;114(10):1527-31
   PubMed Web of Science ®Google Scholar
• Villanueva CM, Fernandez F, Malats N, Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 2003;57(3):166-73
   PubMed Web of Science ®Google Scholar
• Chiou HY, Chiou ST, Hsu YH, Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153(5):411-8
   PubMed Web of Science ®Google Scholar
• Varkarakis MJ, Gaeta J, Moore RH, Murphy GP. Superficial bladder tumor. Aspects of clinical progression. Urology 1974;4(4):414-20
   PubMedGoogle Scholar
• Utz DC, Farrow GM, Rife CC, Carcinoma in situ of the bladder. Cancer 1980;45(7 Suppl):1842-8
   PubMed Web of Science ®Google Scholar
• Messing EM, Young TB, Hunt VB, Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 1989;64(11):2361-7
   PubMed Web of Science ®Google Scholar
• Britton JP, Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ 1989;299(6706):1010-2
   PubMed Web of Science ®Google Scholar
• Messing EM, Madeb R, Young T, Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107(9):2173-9
   PubMed Web of Science ®Google Scholar
• Soloway MS, Briggman V, Carpinito GA, Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156(2 Pt 1):363-7
   PubMed Web of Science ®Google Scholar
• Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60(4):1410-7
   PubMed Web of Science ®Google Scholar
• Fey EG, Penman S. The morphological oncogenic signature. Reorganization of epithelial cytoarchitecture and metabolic regulation by tumor promoters and by transformation. Dev Biol (N Y 1985) 1986;3:81-100
   PubMedGoogle Scholar
• Lekili M, Sener E, Demir MA, Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res 2004;32(2):124-8
   PubMed Web of Science ®Google Scholar
• Sozen S, Biri H, Sinik Z, Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999;36(3):225-9
   PubMed Web of Science ®Google Scholar
• Serretta V, Lo Presti D, Vasile P, Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998;52(5):793-6
   PubMed Web of Science ®Google Scholar
• Zippe C, Pandrangi L, Potts JM, NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999;19(4A):2621-3
   PubMed Web of Science ®Google Scholar
• Miyanaga N, Akaza H, Ishikawa S, Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997;31(2):163-8
   PubMed Web of Science ®Google Scholar
• Oge O, Atsu N, Sahin A, Ozen H. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol 2000;34(6):349-51
   PubMed Web of Science ®Google Scholar
• Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004;172(3):1123-6
   PubMed Web of Science ®Google Scholar
• Halling KC, King W, Sokolova IA, A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167(5):2001-6
   PubMed Web of Science ®Google Scholar
• Babjuk M, Kostirova M, Mudra K, Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002;41(1):34-9
   PubMed Web of Science ®Google Scholar
• Sun Y, He DL, Ma Q, Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl) 2006;119(21):1763-71
   PubMed Web of Science ®Google Scholar
• Toma MI, Friedrich MG, Hautmann SH, Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004;22(2):145-9
   PubMed Web of Science ®Google Scholar
• Pode D, Shapiro A, Wald M, Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161(2):443-6
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Herrero E, Megias J, Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int 1999;84(6):706-13
   PubMed Web of Science ®Google Scholar
• Raitanen MP, Kaasinen E, Rintala E, Prognostic utility of human complement factor H related protein test (the BTA stat Test). Br J Cancer 2001;85(4):552-6
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345(6274):458-60
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011-5
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Structure and function of telomeres. Nature 1991;350(6319):569-73
   PubMed Web of Science ®Google Scholar
• Kavaler E, Landman J, Chang Y, Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82(4):708-14
   PubMed Web of Science ®Google Scholar
• Zakian VA. Life and cancer without telomerase. Cell 1997;91(1):1-3
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61(1):109-18
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Ogawa O, Kakehi Y, Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89(10):724-30
   PubMed Web of Science ®Google Scholar
• Melissourgos N, Kastrinakis NG, Davilas I, Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003;62(2):362-7
   PubMed Web of Science ®Google Scholar
• Lee DH, Yang SC, Hong SJ, Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4(3):535-8
   PubMed Web of Science ®Google Scholar
• Ramakumar S, Bhuiyan J, Besse JA, Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161(2):388-94
   PubMed Web of Science ®Google Scholar
• Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 2000;90(2):75-86
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB, Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35-63
   PubMedGoogle Scholar
• Allard P, Fradet Y, Tetu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995;1(10):1195-202
   PubMed Web of Science ®Google Scholar
• Huland H, Arndt R, Huland E, Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology. J Urol 1987;137(4):654-9
   PubMed Web of Science ®Google Scholar
• Mian C, Pycha A, Wiener H, Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161(5):1486-9
   PubMed Web of Science ®Google Scholar
• Vriesema JL, Aben KK, Witjes JA, Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer 2001;93(5):699-702
   PubMed Web of Science ®Google Scholar
• Feil G, Zumbragel A, Paulgen-Nelde HJ, Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res 2003;23(2A):963-7
   PubMed Web of Science ®Google Scholar
• Sawczuk IS, Pickens CL, Vasa UR, DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002;7(5):185-90
   PubMed Web of Science ®Google Scholar
• Gilbert SM, Veltri RW, Sawczuk A, Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology 2003;61(3):539-43
   PubMed Web of Science ®Google Scholar
• Konety BR, Nguyen TS, Brenes G, Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164(3 Pt 1):634-9
   PubMed Web of Science ®Google Scholar
• Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005;174(1):64-8
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Pesl M, Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71(4):718-22
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Urrutia M, Silva JM, Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165(5):1462-7
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Lurkin I, Radvanyi F, The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61(4):1265-8
   PubMed Web of Science ®Google Scholar
• Cassel A, Rahat MA, Lahat N, Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 2001;166(3):841-4
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE, Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007;51(5):1267-74
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;27(1):53-61
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Schroeder GL, Selzer MG, Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002;95(1):61-72
   PubMed Web of Science ®Google Scholar
• Eissa S, Kassim SK, Labib RA, Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 2005;103(7):1356-62
   PubMed Web of Science ®Google Scholar
• Klein FA, Herr HW, Whitmore WF Jr, An evaluation of automated flow cytometry (FCM) in detection of carcinoma in situ of the urinary bladder. Cancer 1982;50(5):1003-8
   PubMed Web of Science ®Google Scholar
• Acevedo HF, Hartsock RJ. Metastatic phenotype correlates with high expression of membrane-associated complete beta-human chorionic gonadotropin in vivo. Cancer 1996;78(11):2388-99
   PubMed Web of Science ®Google Scholar
• Schapers RF, Smeets AW, Pauwels RP, Cytogenetic analysis in transitional cell carcinoma of the bladder. Br J Urol 1993;72(6):887-92
   PubMedGoogle Scholar
• Gregoire M, Fradet Y, Meyer F, Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol 1997;157(5):1660-4
   PubMed Web of Science ®Google Scholar
• Murphy WM, Emerson LD, Chandler RW, Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol 1986;136(4):815-9
   PubMed Web of Science ®Google Scholar
• Bakhos R, Shankey TV, Flanigan RC, Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases. Diagn Cytopathol 2000;22(2):65-9
   PubMed Web of Science ®Google Scholar
• Bucci B, Pansadoro V, De Paula F, Biologic characteristics of T1 papillary bladder cancer. Flow cytometric study of paraffin-embedded material. Anal Quant Cytol Histol 1995;17(2):121-8
   PubMed Web of Science ®Google Scholar
• Kawamura K, Tanaka T, Ikeda R, DNA ploidy analysis of urinary tract epithelial tumors by laser scanning cytometry. Anal Quant Cytol Histol 2000;22(1):26-30
   PubMed Web of Science ®Google Scholar
• Liedl T. Flow cytometric DNA/cytokeratin analysis of bladder lavage: methodical aspects and clinical implications. Urol Int 1995;54(1):22-47
   PubMed Web of Science ®Google Scholar
• Tribukait B, Esposti PL. Quantitative flow-microfluorometric analysis of the DNA in cells from neoplasms of the urinary bladder: correlation of aneuploidy with histological grading and the cytological findings. Urol Res 1978;6(4):201-5
   PubMed Web of Science ®Google Scholar
• Badalament RA, Kimmel M, Gay H, The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer 1987;59(12):2078-85
   PubMed Web of Science ®Google Scholar
• Giella JG, Ring K, Olsson CA, The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder. J Urol 1992;148(2 Pt 1):293-6
   PubMed Web of Science ®Google Scholar
• Song Z, Sun X, Wu D. Significance of flow cytometry in the diagnosis and treatment of bladder tumors. Chin Med Sci J 1995;10(1):38-41
   PubMedGoogle Scholar
• Bittard H, Lamy B, Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 1996;155(6):1887-91
   PubMed Web of Science ®Google Scholar
• Tetu B, Allard P, Fradet Y, Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. Hum Pathol 1996;27(9):922-6
   PubMed Web of Science ®Google Scholar
• Gourlay W, Chan V, Gilks CB. Screening for urothelial malignancies by cytologic analysis and flow cytometry in a community urologic practice: a prospective study. Mod Pathol 1995;8(4):394-7
   PubMed Web of Science ®Google Scholar
• Cajulis RS, Haines GK III, Frias-Hidvegi D, Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995;13(3):214-23; discussion 224
   PubMed Web of Science ®Google Scholar
• de la Roza GL, Hopkovitz A, Caraway NP, DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol 1996;9(5):571-8
   PubMed Web of Science ®Google Scholar
• Mora LB, Nicosia SV, Pow-Sang JM, Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol 1996;156(1):49-54; discussion 54-5
   PubMed Web of Science ®Google Scholar
• Richman AM, Mayne ST, Jekel JF, Albertsen P. Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma. Cancer 1998;82(9):1738-48
   PubMed Web of Science ®Google Scholar
• Parry WL, Hemstreet GP III. Cancer detection by quantitative fluorescence image analysis. J Urol 1988;139(2):270-4
   PubMed Web of Science ®Google Scholar
• Wojcik EM, Miller MC, O'Dowd GJ, Veltri RW. Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma. Anal Quant Cytol Histol 1998;20(1):69-76
   PubMed Web of Science ®Google Scholar
• Pycha A, Mian C, Haitel A, Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997;157(6):2116-9
   PubMed Web of Science ®Google Scholar
• Sauter G, Gasser TC, Moch H, DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 1997; 25:(Suppl 1):S37-43
   PubMed Web of Science ®Google Scholar
• Sokolova IA, Halling KC, Jenkins RB, The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116-23
   PubMed Web of Science ®Google Scholar
• Skacel M, Fahmy M, Brainard JA, Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169(6):2101-5
   PubMed Web of Science ®Google Scholar
• Placer J, Espinet B, Salido M, Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42(6):547-52
   PubMed Web of Science ®Google Scholar
• Dalquen P, Kleiber B, Grilli B, DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer 2002;96(6):374-9
   PubMed Web of Science ®Google Scholar
• Mao L, Schoenberg MP, Scicchitano M, Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271(5249):659-62
   PubMed Web of Science ®Google Scholar
• Steiner G, Schoenberg MP, Linn JF, Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997;3(6):621-4
   PubMed Web of Science ®Google Scholar
• Linn JF, Lango M, Halachmi S, Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997;74(6):625-9
   PubMed Web of Science ®Google Scholar
• Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000;85(5):614-7
   PubMed Web of Science ®Google Scholar
• Mourah S, Cussenot O, Vimont V, Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer 1998;79(6):629-33
   PubMed Web of Science ®Google Scholar
• Crew JP, O'Brien T, Bradburn M, Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57(23):5281-5
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Gandini O, Gradilone A, Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 1999;14(6):1123-7
   PubMed Web of Science ®Google Scholar
• Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 1994;44(4):502-6
   PubMed Web of Science ®Google Scholar
• Ravery V, Grignon D, Angulo J, Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25(1):9-17
   PubMed Web of Science ®Google Scholar
• Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50(8):2530-7
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84(16):1251-6
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Reuter VE. Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol 1997;14(2):123-32
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85(1):53-9
   PubMed Web of Science ®Google Scholar
• Tsuji M, Kojima K, Murakami Y, Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997;79(3):367-72
   PubMedGoogle Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90(14):1072-9
   PubMed Web of Science ®Google Scholar
• Grossman HB, Liebert M, Antelo M, p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4(4):829-34
   PubMed Web of Science ®Google Scholar
• Prescott JL, Montie J, Pugh TW, Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer 2001;91(11):2127-35
   PubMed Web of Science ®Google Scholar
• Husgafvel-Pursiainen K, Kannio A. Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect 1996;104(Suppl 3):553-6
   PubMedGoogle Scholar
• Zhang ZF, Sarkis AS, Cordon-Cardo C, Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1994;3(1):19-24
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem Mol Morphol 2000;8(4):285-92
   PubMedGoogle Scholar
• Esrig D, Spruck CH III, Nichols PW, p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143(5):1389-97
   PubMed Web of Science ®Google Scholar
• Migaldi M, Sgambato A, Garagnani L, Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6(8):3131-8
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Lipponen P, Raitanen M, Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 2000;28(5):285-92
   PubMed Web of Science ®Google Scholar
• Lehner R, Lucia MS, Jarboe EA, Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002;10(2):134-8
   PubMedGoogle Scholar
• Gazzaniga P, Gradilone A, Giuliani L, Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14(1):85-90
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Karakiewicz PI, Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109(6):1106-13
   PubMed Web of Science ®Google Scholar
• Hausladen DA, Wheeler MA, Altieri DC, Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 2003;170(1):230-4
   PubMed Web of Science ®Google Scholar
• Shariat SF, Casella R, Khoddami SM, Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171(2 Pt 1):626-30
   PubMed Web of Science ®Google Scholar
• Svatek RS, Herman MP, Lotan Y, Soluble Fas – a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106(8):1701-7
   PubMed Web of Science ®Google Scholar
• Schaaf A, Sagi S, Langbein S, Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004;22(3):188-92
   PubMed Web of Science ®Google Scholar
• Popov Z, Hoznek A, Colombel M, The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80(8):1472-81
   PubMed Web of Science ®Google Scholar
• Cohen MB, Waldman FM, Carroll PR, Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 1993;24(7):772-8
   PubMed Web of Science ®Google Scholar
• Blasco-Olaetxea E, Belloso L, Garcia-Tamayo J. Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor. Eur J Cancer 1996;32A(3):444-6
   PubMed Web of Science ®Google Scholar
• Bravo R, Macdonald-Bravo H. Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication. EMBO J 1985;4(3):655-61
   PubMed Web of Science ®Google Scholar
• Fradet Y, Tardif M, Bourget L, Robert J. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group. Cancer Res 1990;50(2):432-7
   PubMed Web of Science ®Google Scholar
• Ravery V, Colombel M, Popov Z, Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 1995;71(1):196-200
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987;329(6141):671-2
   PubMedGoogle Scholar
• Kausch I, Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002;41(1):15-29
   PubMed Web of Science ®Google Scholar
• Bochner BH, Cote RJ, Weidner N, Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87(21):1603-12
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Bromley M, Clarke NW, Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 1999;19(4C):3479-84
   PubMed Web of Science ®Google Scholar
• Grossfeld GD, Ginsberg DA, Stein JP, Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89(3):219-27
   PubMed Web of Science ®Google Scholar
• Mungan U, Kirkali G, Celebi I, Kirkali Z. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder. Urology 1996;48(3):496-500
   PubMed Web of Science ®Google Scholar
• Lipponen PK. Expression of cathepsin D in transitional cell bladder tumours. J Pathol 1996;178(1):59-64
   PubMed Web of Science ®Google Scholar
• Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996;47(1):34-7
   PubMed Web of Science ®Google Scholar
• Kanayama H, Yokota K, Kurokawa Y, Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998;82(7):1359-66
   PubMed Web of Science ®Google Scholar
• Gohji K, Fujimoto N, Ohkawa J, Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998;77(4):650-5
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltoma S, Kosma VM, Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998;186(2):157-64
   PubMed Web of Science ®Google Scholar
• Fontana D, Bellina M, Scoffone C, Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol 1996;29(4):470-6
   PubMed Web of Science ®Google Scholar
• Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995;175(2):203-10
   PubMed Web of Science ®Google Scholar
• Mellon JK, Cook S, Chambers P, Neal DE. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br J Cancer 1996;73(5):654-8
   PubMed Web of Science ®Google Scholar
• Underwood M, Bartlett J, Reeves J, C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995;55(11):2422-30
   PubMed Web of Science ®Google Scholar
• Sato K, Moriyama M, Mori S, An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70(10):2493-8
   PubMed Web of Science ®Google Scholar
• Orlando C, Sestini R, Vona G, Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol 1996;156(6):2089-93
   PubMed Web of Science ®Google Scholar
• Gandour-Edwards R, Lara PN Jr, Folkins AK, Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95(5):1009-15
   PubMed Web of Science ®Google Scholar
• Latif Z, Watters AD, Dunn I, HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004;40(1):56-63
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25(16):2218-24
   PubMed Web of Science ®Google Scholar
• Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin North Am 2000;27(1):25-37
   PubMed Web of Science ®Google Scholar
• Burchardt M, Burchardt T, Shabsigh A, Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46(5):595-605
   PubMed Web of Science ®Google Scholar
• European Association of Urology. www.uroweb.org/guidelines/online-guidelines/
   Google Scholar
• Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003;89(12):2172-7
   PubMed Web of Science ®Google Scholar
• Dyrskjøt L, Thykjaer T, Kruhøffer M, Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33(1):90-6
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim EJ, Jeong P, RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 2005;65(20):9347-54
   PubMed Web of Science ®Google Scholar
• Hotakainen K, Lintula S, Stenman J, Detection of messenger RNA for the beta-subunit of chorionic gonadotropin in urinary cells from patients with transitional cell carcinoma of the bladder by reverse transcription-polymerase chain reaction. Int J Cancer 1999;84(3):304-8
   PubMed Web of Science ®Google Scholar
• Iles RK, Persad R, Trivedi M, Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996;77(1):61-9
   PubMedGoogle Scholar